SEC Form 4 · accession 0001127602-18-028076

HAEMONETICS CORP · HAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Sep 17, 2018

Accepted (ET)

Sep 19, 2018 · 5:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000313143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Sep 17, 2018	M	8,196	$36.37	A	41,555	D
Common Stock^F2	Sep 17, 2018	M	6,573	$45.45	A	48,128	D
Common Stock^F2	Sep 17, 2018	M	10,353	$35.50	A	58,481	D
Common Stock^F3,F2	Sep 17, 2018	S	1,502	$108.92	D	56,979	D
Common Stock^F4,F2	Sep 17, 2018	S	3,696	$110.11	D	53,283	D
Common Stock^F5,F2	Sep 17, 2018	S	13,183	$111.33	D	40,100	D
Common Stock^F6,F2	Sep 17, 2018	S	11,812	$113.16	D	28,288	D
Common Stock^F7,F2	Sep 17, 2018	S	631	$114.16	D	27,657	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Non-qualified Stock Option (Right to Buy)^F8	$36.37	Sep 17, 2018	M	8,196	D	Jul 27, 2013	Jul 27, 2019	Common Stock	8,196	D
Non-qualified Stock Option (Right to Buy)^F8	$45.45	Sep 17, 2018	M	6,573	D	Jul 24, 2014	Jul 24, 2020	Common Stock	6,573	D
Non-qualified Stock Option (Right to Buy)^F8	$35.50	Sep 17, 2018	M	10,353	D	Jul 23, 2015	Jul 23, 2021	Common Stock	10,353	D

F1Transaction pursuant to an existing 10b5-1 trading plan.
F2This number includes unvested restricted stock units previously reported.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.79 to $110.55, inclusive.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.92 to 111.88, inclusive.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.51 to $113.35, inclusive.
F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114 to $114.44, inclusive.
F8Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.